Immunometric assays claiming to determine intact parathyroid hormone (PTH) generally cross-react with N-truncated forms such as PTH(7--84). Laboratories need to examine the relevance of new assays with probable PTH(1--84) speci city. It is logical that assays should measure what they state they do. However, it seems unlikely that use of older 'intact' PTH assays will affect the clinical interpretation of results in primary hyperparathyroidism or vitamin D de ciency. It is plausible that appropriate application of new PTH assays could improve outcome in chronic renal failure. However, it has never been suggested that straightforward replacement of existing assays with new PTH(1--84) assays will lead to this improved outcome. A better understanding of PTH fragments and their interaction with PTH receptors may shed light on the relevance of different PTH assays. In the meantime, older technologies will continue to work well for the vast majority of patients.
Parathyroid hormone (PTH) is a single-chain polypeptide of 84 amino acids. Recent studies 1^10 have forced a re-evaluation of the methodology used for the measurement of PTH. It is now clear that currently used immunometric assays claiming to determine only intact PTH generally show cross-reactivity with N-truncated forms such as PTH(7^84). Marketing by Scantibodies Clinical Laboratories (San Diego CA, USA) in relation to one PTH(1^84) assay has generated considerable attention amongst renal physicians and laboratory managers and has led to the development of at least two other commercial assays with probable PTH(1^84) speci¢city (Immunotopics BioActive PTH ILMA, Immunotopics Inc, San Clemente CA, USA; Nichols BioActive PTH, Nichols Institute of Diagnostics, San Juan Capistrano CA, USA). 9, 10 Most recent studies have involved authorship by the Scantibodies company. 3,5^8 Current terminology is confusing. Immunometric assays which detect N-truncated fragments as well as PTH(1^84) are termed`intact PTH assays'. Assays determining PTH(1^84) alone are variably referred to as`whole' PTH, CAP TM (cyclase-activating PTH), 3rd generation, or Bioactive assays. In this paper, these are referred to as PTH(1^84) assays. CIP TM (cyclase-inactive PTH) refers to N-truncated fragments.
Clinical laboratories need to examine the relevance of these advances. There are three predominant applications of PTH assays: to distinguish between primary hyperparathyroidism and other causes of hypercalcaemia; to provide supplementary information in the diagnosis of vitamin D de¢ciency; and to guide therapeutic strategies for the prevention of renal bone disease.
Is there su¤cient evidence to merit banishment of our current methodologies in favour of these newer assays? In the long term, the answer to this question is clearly`yes'. It is logical that assays claiming to measure only PTH(1^84) should measure what they state they do. In the short term, the urgency with which we institute such change should depend on the magnitude of any possible clinical bene¢t relative to the immediate disadvantages of methodological change. Validated PTH(1^84) assays are expensive and, with the exception of the Nichols Institute BioActive PTH assay, they are not automated. Methodological change involves substantial allocation of resources to verify analytical performance, to generate applicable reference ranges, to gain clinical insight and to adjust clinical protocols based on evidence. It may not be worth expending this e¡ort immediately given current evidence and the likely future availability of other assays.
Comment
The ¢rst question to ask is whether any other currently used assays might also be speci¢c for PTH(1^84). It does seem likely that all commonly used assays detect fragments to at least some degree. This has been investigated using synthetic PTH(7^84) tò spike' samples 2, 5, 6, 9, 11 and using high-performance liquid chromatography (HPLC) to separate immunoreactive PTH. 2,4,9 PTH(7^84) is usually cited as the likely cross-reacting peptide, but it is by no means certain that this is the only analytically relevant N-terminal truncated fragment, and HPLC may not be able to distinguish between PTH(7^84) and larger N-truncated fragments. Absence of crossreactivity with synthetic PTH(7^84) implies that an assay is more speci¢c for PTH(1^84), but larger fragments may still be detected. Cross-reactivity with PTH(7^84) was assessed in the May 2001 distribution of the UK National External Quality Assurance Scheme (UK NEQAS) by the addition of synthetic PTH(7^84) to a pool of normal serum. After correcting for between-method di¡erences in calibration, cross-reactivity with added PTH(7^84) ranged between 27% and 59% for di¡erent assays. Cross-reactivity in the Roche Elecsys assay (F. Ho¡man-La Roche Ltd, Basel, Switzerland) was 53%, although one earlier study 11 had showed that this assay might not react with PTH(7^84).
N-terminal truncated PTH is likely to represent approximately 10^20% of PTH(1^84) in healthy individuals and in primary hyperparathyroidism. 1, 4, 6 In chronic renal failure (CRF) the concentration of PTH(1^84) rises, as does the concentration of Ntruncated fragments. 5^7,9 N-truncated forms of PTH probably arise from the parathyroid gland itself rather than by di¡erential accumulation caused by renal disease. 5 The ratio of N-truncated fragments to PTH(1^84) may increase to 35% or more in end-stage renal failure, 4, 6 although this disproportionate increase is not a consistent ¢nding. On the basis of cross-reactivity estimates from the NEQAS exercise, somewhere between 5% and 10% of immunoreactive PTH represents cross-reactivity with N-truncated fragments if current assays are used in healthy individuals, and perhaps as much as 50% with some assays in CRF. There is as yet little evidence that the di¡erences between these assays will materially in£uence clinical management in the majority of patients.
It seems extremely unlikely that use of PTH(1^84) assays will a¡ect the clinical interpretation of results in primary hyperparathyroidism or vitamin D de¢ciency. The proportion of non-PTH(1^84) detected in these patients is likely to be approximately 10% with most assays; it does not appear to vary much between subjects and is incorporated in current reference ranges. This also has to be considered in the context of random, circadian and seasonal changes in PTH, which may be substantial.
One study showed that a somewhat higher proportion of individuals with mild primary hyperparathyroidism was detected using a PTH(1^84) assay when the upper limit of the PTH reference range (URL) was used as a diagnostic threshold. 12 However, the notion that the URL should serve as a diagnostic threshold to distinguish between primary hyperparathyroidism and other causes of hypercalcaemia is £awed. In addition, when assays are compared using the URL in this way, it is important to know that reference limits were generated using identical subjects, and that the number of subjects was large enough to de¢ne this limit accurately. Another study 9 found that the diagnostic discrimination between patients with primary hyperparathyroidism and controls was similar whether a traditional`intact' PTH assay (Nichols Advantage Intact-PTH) or a PTH(1^84) assay (Nichols Bio-Intact PTH) was used. The proportion of patients with low serum 25(OH) vitamin D who have elevated PTH is also the same whether fragment-detecting or PTH(1^84) assays are used. 13 It is plausible that appropriate application of new PTH(1^84) assays could improve outcome in CRF. Detailed discussion is beyond the scope of this article. However, it has never been suggested that straightforward replacement of existing assays with new PTH(1^84) assays will lead to this improved outcome. Indeed, several studies have shown that there is an excellent correlation (r*0¢97) between assays detecting only PTH(1^84) and conventional N-truncated fragment-detecting assays in CRF, 5^7,9 although fragment-detecting assays do show a proportionate positive bias. Consequently, the proportion of patients with CRF with elevated PTH, as well as the relative magnitude of the elevation above the assay-speci¢c reference range, are almost identical for PTH(1^84) and fragment-detecting assays. 8 The more relevant issue is that N-truncated PTH fragments may act as endogenous inhibitors of PTH action 5, 14 (at least in animals and in vitro), and that it may be useful to estimate their concentration. There is also a growing body of evidence suggesting that PTH fragments might interact with the PTH/PTHrP receptor (PTH1R) and that other parts of the PTH molecule such as the carboxyterminal portion may have speci¢c receptors. 14 The relevance of these receptors and ligands in CRF is unknown.
There is a proposal that current PTH assays should be replaced in CRF by two simultaneous PTH assays, (a) a PTH(1^84) assay, and (b) an assay that detects both PTH(1^84) and fragments, in order to calculate the concentration of fragments which could inhibit PTH action. The relative proportion of fragments is expressed as the so-called CAP TM /CIP TM ratio for Scantibodies assays (equivalent to (a)/[(b)7(a)] above). This approach has been examined in one recent study which deserves careful review. 8 The study examined the ability of PTH(1^84) or (CAP TM ), intact' PTH, or the CAP TM /CIP TM ratio to predict activation frequency in iliac crest bone samples in CRF. Activation frequency is the rate at which bone remodelling cycles are initiated. It was claimed that the CAP TM /CIP TM ratio was the best predictor of activation frequency. It is clear from examination of the raw data shown in this paper that there is no di¡erence between the ability of PTH(1^84) and the fragment-detecting assay to predict activation frequency. The ability of the CAP TM /CIP TM ratio to predict activation frequency also appears roughly similar. All predictors as well as activation frequency are of course continuous variables. Unfortunately, correlation coe¤cients were not calculated or compared, the authors choosing instead to dichotomiz e their data using somewhat arbitrarily placed lines (1¢0 in the case of CAP TM /CIP TM ). In another study, only one patient of 99 studied with CRF had a CAP TM /CIP TM ratio 51, the level said to carry risk for adynamic (low turnover) bone disease. 7 When PTH is markedly elevated (as it is in many patients with CRF) the choice of assay is probably irrelevant.
Measurement of PTH using current fragmentdetecting assays overestimates the severity of hyperparathyroid bone disease in CRF. 15 This is likely to be due to inhibitors of PTH action and not to detection of PTH fragments by current PTH assays. Thus, current protocols recommend maintaining PTH at two to three times the URL using conventional PTH assays, in order to prevent adynamic bone disease. 16 If PTH(1^84) assays are used in CRF it is essential that clinicians understand that they do not provide information that is markedly di¡erent from current fragment-detecting assays. Users of new PTH(1^84) assays might be led to believe that the reference range is an appropriate target in the absence of fragment detection. However, the proportionate increase of PTH above the URL in CRF is almost identical, whichever assay is used. 8 Misinformed attempts to target PTH(1^84) to the reference range may result in adynamic bone disease.
In conclusion, (a) it is important that assays measure what they say they do, (b) what is required is evolution to methods that measure PTH(1^84) alone, not an urgent shift to unfamiliar and expensive methods that might make a di¡erence in a small number of patients, and (c) mathematical combinations of methods must show themselves to be clinically superior in independent studies using appropriate endpoints. A better understanding of the physiology of PTH and its fragments as well as their interaction with PTH receptors may shed new light on the relevance of di¡erent PTH assays in health and disease. In the meantime, older technologies will continue to work well for the vast majority of patients.
